SEC Filing Summary: Pieris Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on September 5, 2018. The registrant is a Nevada corporation with principal executive offices in Boston, MA. The filing serves as a Regulation FD disclosure to disseminate information presented at the September 2018 Rodman & Renshaw Global Investment Conference.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation and does not contain audited financial statements or a summary of financial results.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The document solely references the attachment of an investor conference presentation.
Guidance, Outlook, and Risks
The filing incorporates by reference a presentation from the Rodman & Renshaw Global Investment Conference. However, the text of the 8-K explicitly states that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, specific guidance, outlook, or risk factors contained within the presentation are not summarized in this filing text.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Rodman & Renshaw Global Investment Conference Presentation) for specific business updates.
- Note that the presentation materials are not legally "filed" and are not incorporated by reference into other SEC filings unless explicitly stated.
- Confirm the company's status as an Emerging Growth Company, as indicated by the checkmark in the filing.
- Review subsequent filings for actual financial results, as this 8-K contains no numerical financial data.